All In Biotech

Drug Trial Radar · NCT06879717

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

A Phase I/IIa Study of Roginolisib in Combination With Dostarlimab With or Without Docetaxel in Patients With Advanced Non-squamous NSCLC Who Have Progressed on Standard of Care Immune Checkpoint Therapy and Platinum Doublet Chemotherapy or Standard Immunotherapy Without Chemotherapy (PULMO-1)

Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Apr 22, 2025

Primary completion

Jan 2027

Study completion Jan 2028

Sponsor

Lead sponsor
iOncturaIndustry
Sponsor type
Industry
First posted
Mar 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn how roginolisib works in combination with dostarlimab with or without docetaxel in adult patients with advanced non small-cell lung cancer. The main questions it aims to answer are: To compare across the treatment arms the proportion of patients with a reduction in Treg cells To evaluate the safety and tolerability of roginolisib plus dostarlimab, with or without docetaxel

Conditions

  • Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  • Advanced Non Squamous NSCLC

Interventions

  • roginolisibDrug

    tablet, 40mg tablet strength

  • DostarlimabDrug

    500 mg administered as IV infusion

  • DocetaxelDrug

    75 mg/m2 administered over 1 hour as IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE V5Time frame: On Day 1 and Day 15 of Cycle 1; Day 1 of Cycle 2 onwards. Each cycle is 21 days
  2. To compare across treatment arms the proportion of patients with a reduction in peripheral blood Tregs (for example as defined by CD4+CD25+CD127- expression)Time frame: On Day 1 of each Cycle. Cycle length is 21 days
  3. Number of Participants With changes in laboratory parametersTime frame: On Day 1and Day 15 of Cycle 1; Day 1 of Cycle 2 onwards. Each cycle is 21 days
  4. Number of Participants with Changes in ECG from baselineTime frame: On Day 1 and Day 15 of Cycle 1; Day 1 of Cycle 2 onwards. Each cycle is 21 days
  5. Number of Participants With Change on Physical Examination from BaselineTime frame: On Day 1and Day 15 of Cycle 1; Day 1 of Cycle 2 onwards. Each cycle is 21 days

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Antwerp University Hospital

    Antwerp, Belgium

  • AZ Delta VZW

    Roeselare, Belgium

  • Istituto Romagnolo per lo studio dei Tumori "Dino Amadori"

    Meldola, Forlì-Cesena, Italy

  • Humanitas University, Department of Medical Oncology

    Rozzano, Milan, Italy

  • Institut Català d'Oncologia Hospitalet

    Barcelona, Spain

  • Hospital Universitari Son Espases

    Palma, Spain

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.